Equity Overview
Price & Market Data
Price: $64.19
Daily Change: +$3.59 / 5.59%
Daily Range: $61.26 - $64.36
Market Cap: $3,179,154,432
Daily Volume: 223,996
Performance Metrics
1 Week: 28.64%
1 Month: 87.52%
3 Months: 137.0%
6 Months: 210.4%
1 Year: 830.7%
YTD: 108.2%
Company Details
Employees: 68
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.